designed to reduce severe heart attack impairment when used as an adjunct therapy with angioplasty in acute STEMI and NSTEMI patients. Company appoints Cajetan von König as Director of Sales and ...
VIENNA, Austria - Miracor Medical Systems announced today that results from the ‘Prepare RAMSES’ clinical trial will be disclosed at ‘TCT 2014’ in Washington, D.C. The Prepare RAMSES trial was a ...
AWANS, Belgium--(BUSINESS WIRE)--Miracor Medical SA (Miracor Medical) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its PiCSO ® Impulse System for ...
PARIS – Miracor Medical SA secured a $28 million series E funding round for its Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) impulse system, intended for treating patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results